Brief Report: Suspected Cannabis-Induced Mania and Psychosis in Young Adult Males with Autism Spectrum Disorder / Majd AL-SOLEITI in Journal of Autism and Developmental Disorders, 52-9 (September 2022)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 52-9 (September 2022) . - p.4164-4171 Titre : Brief Report: Suspected Cannabis-Induced Mania and Psychosis in Young Adult Males with Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Majd AL-SOLEITI, Auteur ; Kayla BALAJ, Auteur ; Robyn P. THOM, Auteur ; Christopher J. MCDOUGLE, Auteur ; Christopher J. KEARY, Auteur Article en page(s) : p.4164-4171 Langues : Anglais (eng) Mots-clés : Autism Spectrum Disorder/diagnosis/etiology  Cannabis  Humans  Male  Mania  Psychotic Disorders/etiology  Retrospective Studies  Young Adult  Autism  Autism spectrum disorder  Cannabidiol  Clinical trials  Delta-9-tetrahydrocannabinol Index. décimale : PER Périodiques Résumé : There is increasing interest in investigating cannabis for behavioral symptoms in individuals with autism spectrum disorder (ASD). The potential role of dysregulated cannabinoid signaling contributing to the pathophysiology of ASD is an area of active investigation. Results from retrospective and uncontrolled trials of cannabis in subjects with ASD have been published, reporting both potential benefits and adverse effects. Here, we describe the clinical course of three young adult males with ASD who developed mania or psychosis after the consistent use of cannabidiol and delta-9-tetrahydrocannabinol. Caution should be utilized with cannabis use in individuals with ASD until large-scale, replicated randomized controlled trials demonstrating efficacy, safety and tolerability have been published. En ligne : http://dx.doi.org/10.1007/s10803-021-05254-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=486 [article] Brief Report: Suspected Cannabis-Induced Mania and Psychosis in Young Adult Males with Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Majd AL-SOLEITI, Auteur ; Kayla BALAJ, Auteur ; Robyn P. THOM, Auteur ; Christopher J. MCDOUGLE, Auteur ; Christopher J. KEARY, Auteur . - p.4164-4171. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 52-9 (September 2022) . - p.4164-4171 Mots-clés : Autism Spectrum Disorder/diagnosis/etiology  Cannabis  Humans  Male  Mania  Psychotic Disorders/etiology  Retrospective Studies  Young Adult  Autism  Autism spectrum disorder  Cannabidiol  Clinical trials  Delta-9-tetrahydrocannabinol Index. décimale : PER Périodiques Résumé : There is increasing interest in investigating cannabis for behavioral symptoms in individuals with autism spectrum disorder (ASD). The potential role of dysregulated cannabinoid signaling contributing to the pathophysiology of ASD is an area of active investigation. Results from retrospective and uncontrolled trials of cannabis in subjects with ASD have been published, reporting both potential benefits and adverse effects. Here, we describe the clinical course of three young adult males with ASD who developed mania or psychosis after the consistent use of cannabidiol and delta-9-tetrahydrocannabinol. Caution should be utilized with cannabis use in individuals with ASD until large-scale, replicated randomized controlled trials demonstrating efficacy, safety and tolerability have been published. En ligne : http://dx.doi.org/10.1007/s10803-021-05254-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=486

Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series / Robyn P. THOM in Journal of Autism and Developmental Disorders, 50-2 (February 2020)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 50-2 (February 2020) . - p.676-682 Titre : Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series Type de document : Texte imprimé et/ou numérique Auteurs : Robyn P. THOM, Auteur ; Christopher J. KEARY, Auteur ; Jessica L. WAXLER, Auteur ; Barbara R. POBER, Auteur ; Christopher J MCDOUGLE, Auteur Article en page(s) : p.676-682 Langues : Anglais (eng) Mots-clés : Anxiety  Buspirone  Williams syndrome Index. décimale : PER Périodiques Résumé : Co-morbid anxiety disorders, including generalized anxiety disorder (GAD), are highly prevalent among individuals with Williams syndrome (WS). However, reports of the pharmacologic treatment of only a limited number of previous anxiety disorders in WS have appeared in the literature. Here, we review the case histories of three adolescents/young adults with WS and the treatment course of co-morbid GAD with buspirone. Treatment with buspirone was well-tolerated and resulted in sustained response in all three cases. Common medical disorders in WS are highlighted with regards to safe and appropriate pharmacologic treatment of GAD. Buspirone's generally benign side effect profile is a major benefit of its use for treating GAD in individuals with WS. En ligne : http://dx.doi.org/10.1007/s10803-019-04301-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=416 [article] Buspirone for the Treatment of Generalized Anxiety Disorder in Williams Syndrome: A Case Series [Texte imprimé et/ou numérique] / Robyn P. THOM, Auteur ; Christopher J. KEARY, Auteur ; Jessica L. WAXLER, Auteur ; Barbara R. POBER, Auteur ; Christopher J MCDOUGLE, Auteur . - p.676-682. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 50-2 (February 2020) . - p.676-682 Mots-clés : Anxiety  Buspirone  Williams syndrome Index. décimale : PER Périodiques Résumé : Co-morbid anxiety disorders, including generalized anxiety disorder (GAD), are highly prevalent among individuals with Williams syndrome (WS). However, reports of the pharmacologic treatment of only a limited number of previous anxiety disorders in WS have appeared in the literature. Here, we review the case histories of three adolescents/young adults with WS and the treatment course of co-morbid GAD with buspirone. Treatment with buspirone was well-tolerated and resulted in sustained response in all three cases. Common medical disorders in WS are highlighted with regards to safe and appropriate pharmacologic treatment of GAD. Buspirone's generally benign side effect profile is a major benefit of its use for treating GAD in individuals with WS. En ligne : http://dx.doi.org/10.1007/s10803-019-04301-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=416

Case Reports: Clozapine for the Treatment of Catatonia in Autism Spectrum Disorder / Robyn P. THOM in Journal of Autism and Developmental Disorders, 52-6 (June 2022)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 52-6 (June 2022) . - p.2855-2858 Titre : Case Reports: Clozapine for the Treatment of Catatonia in Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : Robyn P. THOM, Auteur ; Christopher J. MCDOUGLE, Auteur Article en page(s) : p.2855-2858 Langues : Anglais (eng) Mots-clés : Autism spectrum disorder  Catatonia  Clozapine Index. décimale : PER Périodiques Résumé : Catatonia is a severe clinical syndrome which has been increasingly reported in autism spectrum disorder (ASD). The prevalence of catatonia in ASD is unknown. Diagnosing catatonia in ASD is complicated by overlapping clinical features such as mutism, stereotypies, and echophenomena. Here, we present the clinical histories of two individuals with ASD and catatonia who were successfully treated with clozapine. We have reported on a novel potential treatment option for catatonia in ASD. Additional studies are needed to evaluate the safety, efficacy, and tolerability of clozapine for the treatment of catatonia in ASD. En ligne : http://dx.doi.org/10.1007/s10803-021-05149-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=475 [article] Case Reports: Clozapine for the Treatment of Catatonia in Autism Spectrum Disorder [Texte imprimé et/ou numérique] / Robyn P. THOM, Auteur ; Christopher J. MCDOUGLE, Auteur . - p.2855-2858. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 52-6 (June 2022) . - p.2855-2858 Mots-clés : Autism spectrum disorder  Catatonia  Clozapine Index. décimale : PER Périodiques Résumé : Catatonia is a severe clinical syndrome which has been increasingly reported in autism spectrum disorder (ASD). The prevalence of catatonia in ASD is unknown. Diagnosing catatonia in ASD is complicated by overlapping clinical features such as mutism, stereotypies, and echophenomena. Here, we present the clinical histories of two individuals with ASD and catatonia who were successfully treated with clozapine. We have reported on a novel potential treatment option for catatonia in ASD. Additional studies are needed to evaluate the safety, efficacy, and tolerability of clozapine for the treatment of catatonia in ASD. En ligne : http://dx.doi.org/10.1007/s10803-021-05149-8 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=475

Diversity of Participants in Williams Syndrome Intervention Studies / Eva SHIN in Journal of Autism and Developmental Disorders, 54-10 (October 2024)  

Public ISBD [article]  inJournal of Autism and Developmental Disorders > 54-10 (October 2024) . - p.3888-3898 Titre : Diversity of Participants in Williams Syndrome Intervention Studies Type de document : Texte imprimé et/ou numérique Auteurs : Eva SHIN, Auteur ; Caitlin RAVICHANDRAN, Auteur ; Danielle RENZI, Auteur ; Barbara R. POBER, Auteur ; Christopher J. MCDOUGLE, Auteur ; Robyn P. THOM, Auteur Article en page(s) : p.3888-3898 Langues : Anglais (eng) Index. décimale : PER Périodiques Résumé : Purpose: This study describes participant diversity in Williams syndrome (WS) intervention studies. Methods: A literature search was conducted to identify prospective treatment studies including participants with WS. Data was extracted on the reporting of and information provided on age, sex, cognitive ability, socioeconomic status, race, and ethnicity. Results: Eleven eligible articles were identified. Reporting rates of demographic factors varied considerably, with the highest rates for age and sex (100%) and the lowest reporting rates for race (18%) and ethnicity (9%). Combining demographic data from the two studies that reported on race and/or ethnicity (n = 33), 88% of participants were White. The combined participant mean age was 20.9 years. Conclusion: There is a low frequency of reporting on several demographic factors including socioeconomic status, race, and ethnicity in WS intervention studies. There is a need for increased representation of racial and ethnic minority groups, older participants, and more cognitively impaired patients in WS research. En ligne : https://doi.org/10.1007/s10803-023-06088-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=536 [article] Diversity of Participants in Williams Syndrome Intervention Studies [Texte imprimé et/ou numérique] / Eva SHIN, Auteur ; Caitlin RAVICHANDRAN, Auteur ; Danielle RENZI, Auteur ; Barbara R. POBER, Auteur ; Christopher J. MCDOUGLE, Auteur ; Robyn P. THOM, Auteur . - p.3888-3898. Langues : Anglais (eng) in Journal of Autism and Developmental Disorders > 54-10 (October 2024) . - p.3888-3898 Index. décimale : PER Périodiques Résumé : Purpose: This study describes participant diversity in Williams syndrome (WS) intervention studies. Methods: A literature search was conducted to identify prospective treatment studies including participants with WS. Data was extracted on the reporting of and information provided on age, sex, cognitive ability, socioeconomic status, race, and ethnicity. Results: Eleven eligible articles were identified. Reporting rates of demographic factors varied considerably, with the highest rates for age and sex (100%) and the lowest reporting rates for race (18%) and ethnicity (9%). Combining demographic data from the two studies that reported on race and/or ethnicity (n = 33), 88% of participants were White. The combined participant mean age was 20.9 years. Conclusion: There is a low frequency of reporting on several demographic factors including socioeconomic status, race, and ethnicity in WS intervention studies. There is a need for increased representation of racial and ethnic minority groups, older participants, and more cognitively impaired patients in WS research. En ligne : https://doi.org/10.1007/s10803-023-06088-2 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=536

---

1 (1 - 4 / 4)